Effects of Maternal Sildenafil Treatment on Vascular Function in Growth-Restricted Fetal Sheep.
Acetylcholine
/ pharmacology
Animals
Birth Weight
/ drug effects
Brain
/ drug effects
Cardiac Output
/ drug effects
Cerebrovascular Circulation
/ drug effects
Female
Fetal Blood
/ chemistry
Fetal Development
/ drug effects
Fetal Growth Retardation
/ chemically induced
Guanylate Cyclase
/ analysis
Male
Muscle, Smooth, Vascular
/ drug effects
Nitric Oxide
/ physiology
Nitroprusside
/ pharmacology
Organ Size
/ drug effects
Placenta
/ blood supply
Pregnancy
Prenatal Injuries
/ chemically induced
Sheep
Sildenafil Citrate
/ blood
Vasodilation
/ drug effects
Vasodilator Agents
/ toxicity
fetus
myography
placenta
sheep
sildenafil citrate
Journal
Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
pubmed:
8
3
2019
medline:
14
1
2020
entrez:
8
3
2019
Statut:
ppublish
Résumé
Objective- The objective of this study was to investigate the effect of intravenous maternal sildenafil citrate (SC) administration on vascular function in growth-restricted fetal sheep. Approach and Results- Fetal growth restriction (FGR) results in cardiovascular adaptations that redistribute cardiac output to optimize suboptimal intrauterine conditions. These adaptations result in structural and functional cardiovascular changes, which may underlie postnatal neurological and cardiovascular sequelae. Evidence suggests SC, a potent vasodilator, may improve FGR. In contrast, recent clinical evidence suggests potential for adverse fetal consequence. Currently, there is limited data on SC effects in the developing fetus. We hypothesized that SC in utero would improve vascular development and function in an ovine model of FGR. Preterm lambs (0.6 gestation) underwent sterile surgery for single umbilical artery ligation or sham (control, appropriately grown) surgery to replicate FGR. Ewes received continuous intravenous SC (36 mg/24 h) or saline from surgery until 0.83 gestation. Fetuses were delivered and immediately euthanized for collection of femoral and middle cerebral artery vessels. Vessel function was assessed via in vitro wire myography. SC exacerbated growth restriction in growth-restricted fetuses and resulted in endothelial dysfunction in the cerebral and femoral vasculature, irrespective of growth status. Dysfunction in the cerebral circulation is endothelial, whereas smooth muscle in the periphery is the origin of the deficit. Conclusions- SC crosses the placenta and alters key fetal vascular development. Extensive studies are required to investigate the effects of SC on fetal development to address safety before additional use of SC as a treatment.
Identifiants
pubmed: 30841708
doi: 10.1161/ATVBAHA.119.312366
doi:
Substances chimiques
Vasodilator Agents
0
Nitroprusside
169D1260KM
Nitric Oxide
31C4KY9ESH
Sildenafil Citrate
BW9B0ZE037
Guanylate Cyclase
EC 4.6.1.2
Acetylcholine
N9YNS0M02X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM